PMC-402


Indications

Solid tumors


Mechanism of action / Target

PMC-402 is a monoclonal antibody that targets the human TIE2 that regulated activation, proliferation, and repolarization of Tie2 expressing macrophages, resulting in T cell activation. It binds to TIE2 expressing macrophages that activate T cells in the tumor microenvironment (TME).


Status

An increase in T cell activity along with a shift in polarization from M2 to M1 macrophages have been identified in the in an vitro study. PharmAbcine initiated the GLP-tox study of PMC-402 in 1Q21 and expects an IND filing in 1Q22.


Publications

* The preclinical data presentation at AACR 2020





     2F, Research Building 2, 70,

     Yuseong-daero 1689 beon-gil,
     Yuseong-gu, Daejeon, 34047, Republic of Korea


     HQ +82-42-863-2017 

     R&D Center +82-42-861-2017

     Investor Relations +70-4294-6097 

     FAX +82-42-863-2080 


     COPYRIGHT BY PharmAbcine Inc.

     ALL RIGHTS RESERVE